Information Provided By: 
Fly News Breaks for May 21, 2015
AMGN, SNY, REGN
May 21, 2015 | 14:48 EDT
Piper Jaffray noted that Regeneron (REGN) shares are at all-time highs after the company and partner Sanofi reported Phase IIb data on Dupilumab and Phase III data on Sarilumab. However, the firm believes the primary driver for Regeneron remains Praluent and firm expects launch costs to outstrip sales growth. Piper acknowledges Regeneron has "one of the richest pipelines in all of biotech," but it sees risk around Amgen's (AMGN) patent suit and keeps its Neutral rating and $484 price target on the stock.
News For REGN;SNY;AMGN From the Last 2 Days
SNY
Apr 22, 2024 | 12:15 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
SNY
Apr 22, 2024 | 11:36 EDT
